A Benchmark, Expand, and Calibration (BenchExCal) Trial Emulation Approach for Using Real‐World Evidence to Support Indication Expansions: Design and Process for a Planned Empirical Evaluation
Open Access
- 11 March 2025
- journal article
- Published by Wiley in Clinical Pharmacology & Therapeutics
- Vol. 117 (6) , 1820-1828
Abstract
Real‐world evidence involving healthcare database studies is well established for making causal inferences in post‐market drug safety studies and methods, data, and research infrastructure for evaluating effectiveness have advanced in recent years. The rapidly expanding field of etiologic research using insurance claims and electronic health records databases is being evaluated for supporting effectiveness claims. One such use case to support regulatory decision‐making on effectiveness is for expanding indications beyond existing effectiveness claims. Confidence in the validity of findings from cohort studies conducted using databases (hereafter “database study”) to support indication expansions could be increased through a structured benchmarking process of an initial database study against RCT evidence followed by calibration of a subsequent database study based on differences in results observed in the initial RCT‐database pair. This paper proposes a benchmark, expand, and calibration (BenchExCal) approach to trial emulation and describes the design and process for evaluating the performance of the approach through both simulation studies; five planned empirical examples are also described. The project will provide insights regarding how a first‐stage benchmarking emulation of a completed trial for an existing indication can be used to calibrate, increase confidence, and improve interpretation of the results for a second‐stage emulation of a hypothetical trial that could potentially provide evidence for an expanded indication. Although the examples have been selected to provide a variety of learnings, five use cases do not address all clinical and data scenarios that may be encountered when seeking a supplemental indication for a marketed drug.Keywords
This publication has 36 references indexed in Scilit:
- Data Checks Before Registering Study Protocols for Health Care Database AnalysesJAMA, 2024
- Prospective benchmarking of an observational analysis in the SWEDEHEART registry against the REDUCE-AMI randomized trialEuropean Journal of Epidemiology, 2024
- Emulation of Randomized Clinical Trials With Nonrandomized Database AnalysesJAMA, 2023
- Emulation Differences vs. Biases When Calibrating Real‐World Evidence Findings Against Randomized Controlled TrialsClinical Pharmacology & Therapeutics, 2020
- Nonrandomized Real‐World Evidence to Support Regulatory Decision Making: Process for a Randomized Trial Replication ProjectClinical Pharmacology & Therapeutics, 2019
- Evaluating the Use of Nonrandomized Real‐World Data Analyses for Regulatory Decision MakingClinical Pharmacology & Therapeutics, 2019
- Strengthening standards, transparency, and collaboration to support medicine evaluation: Ten years of the European Network of Centres for Pharmacoepidemiology and Pharmacovigilance (ENCePP)Pharmacoepidemiology and Drug Safety, 2018
- When and How Can Real World Data Analyses Substitute for Randomized Controlled Trials?Clinical Pharmacology & Therapeutics, 2017
- Negative Control OutcomesJAMA, 2016
- The FDA's sentinel initiative—A comprehensive approach to medical product surveillanceClinical Pharmacology & Therapeutics, 2015